Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
|
US |
|
Apollo Silver Corp
XTSX:APGO
|
CA |
|
O
|
Opendoor Technologies Inc
F:25M
|
US |
|
Holaluz Clidom SA
F:4H2
|
ES |
|
Tokai Tokyo Financial Holdings Inc
F:TO91
|
JP |
|
B
|
Bumech SA
WSE:BMC
|
PL |
|
I
|
ITmedia Inc
TSE:2148
|
JP |
|
Shinkin Central Bank
TSE:8421
|
JP |
|
N
|
Northrop Grumman Corp
XMUN:NTH
|
US |
|
AMN Healthcare Services Inc
NYSE:AMN
|
US |
|
Orthofix Medical Inc
F:OM2
|
US |
|
A
|
argenx SE
F:1AE
|
NL |
|
Intermap Technologies Corp
TSX:IMP
|
US |
Intrinsic Value
Is GLUE undervalued or overvalued?
See the intrinsic value estimate for Monte Rosa Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
GLUE looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with GLUE’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Monte Rosa Therapeutics Does
Monte Rosa Therapeutics is a drug discovery company focused on a newer approach called targeted protein degradation. Instead of blocking a disease-causing protein, it designs small molecules that help the cell’s own cleanup machinery break that protein down. Its main work is to build medicines called molecular glues, which are meant to make hard-to-treat proteins easier to eliminate.
- Headquarters
- United States of America US
- Employees
- 187
- IPO date
- Jun 24, 2021
Monte Rosa Therapeutics has no economic moat
Monte Rosa Therapeutics Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Earnings Waterfall
Monte Rosa Therapeutics Inc
The intrinsic value for Monte Rosa Therapeutics Inc (GLUE) under the Base Case is hidden USD.
Compared with the current market price of 10.49 USD, the stock appears hidden.